

Market Snapshot (Updated at 8AM)

Indian Indices	Close	Net Chng.	Chng. (%)
Sensex	62181.67	389.01	0.62
Nifty	18496.60	112.75	0.61

Global Indices	Close	Net Chng.	Chng. (%)
DOW JONES	33476.46	305.02	0.90
NASDAQ COM.	11004.62	77.38	0.70
FTSE 100	7476.63	4.46	0.06
CAC 40	6677.64	30.33	0.46
DAX	14370.72	106.16	0.74
NIKKEI 225	27824.10	78.13	0.28
SHANGHAI	3192.40	15.04	0.47
HANG SENG	19660.04	243.92	1.23

Currency	Close	Net Chng.	Chng. (%)
USD / INR	82.28	0.16	0.19
USD / EUR	1.05	0.00	0.29
USD / GBP	1.22	0.00	0.35
USD / JPY	136.93	0.37	0.27

Precious Metals	Close	Net Chng.	Chng. (%)
Gold (USD)	1788.30	9.34	0.52
Silver	23.50	0.21	0.89

Energy	Close	Net Chng.	Chng. (%)
NYMEX Crude	71.34	0.33	0.46
Brent Crude	76.20	0.13	0.17
Natural Gas	6.88	0.62	9.98

Bond	Close	Net Chng.	Chng. (%)
10 Yrs G-Sec	7.30	0.01	0.14

Indian ADRs	Close	Net Chng.	Chng. (%)
Dr. Reddy's Lab	53.85	0.14	0.26
HDFC Bank	68.70	0.67	0.98
ICICI Bank	22.72	0.13	0.57
Infosys Ltd	18.49	1.09	5.57
Tata Motors	24.72	0.24	0.96
Wipro	4.71	0.22	4.46

Institutional Flow (In Crore) 09-12-2022

Institution	Purchase	Sale	Net
FII	7515.54	7673.55	158.01
DII	6555.25	6053.62	501.63

Key Contents

- ⇒ [Market Outlook/Recommendation](#)
- ⇒ [Today's Highlights](#)
- ⇒ [Global News, Views and Updates](#)
- ⇒ [Links to important News highlight](#)

Top News for Today

- **Kalpataru Power Transmission:** The company raised Rs 99 crore via allotment of non-convertible debentures on a private placement basis.
- **PSP Projects:** The company received a letter of intent from Nila Spaces for a project worth Rs 121.51 crore to construct high-rise residential towers.
- **Emami:** The company increased its shareholding in subsidiary Brillare Science from 77.53% to 80.59%.
- **Bank of Baroda:** The bank hike MCLR rates in the range of 25-30 basis points across tenors, with effect from Dec. 12.
- **IDFC:** The scheme of amalgamation for the merger of wholly owned subsidiary companies IDFC Alternatives, IDFC Trustee Co., IDFC Projects with IDFC became operative from Dec. 9.
- **Bharti Airtel:** After receipt of notice for conversion of FCCBs of principle value of \$8.6 mn from certain holders of FCCBs, board members have approved allotment of 11.88 lakh shares at conversion price of Rs 521 per share to such FCCBs holders.
- **Himatsingka Seide:** Board will meet on December 15 to consider fund raising up to Rs 108 crore. They will also consider an issue of NCDs up to Rs 500 crore, to identified investors.
- **NTPC:** Commences commercial operations of first part capacity of 162.27 MW out of 230 MW Ettayapuram Solar PV Project.
- **Jaypee Power:** Meeting of board to apprise the board of the recommendations of the audit committee to consider the proposal of divestment of Jaypee Nigrie Cement Grinding Unit.
- **Zydus Lifesciences:** Receives two final approvals from the USFDA for Silodosin capsules and Pregabalin capsules The drugs will be manufactured at the group's formulation manufacturing facility at Moraiya, Ahmedabad, India. Silodosin capsules had annual sales of \$14 million in the United States according to IQVIA data. Pregabalin capsules had annual sales of \$242 million in the United States according to IQVIA data.

Events of the Day

- **SRF:** To meet investors and analysts on Dec. 12 and Dec. 13.
- **Indo Count Industries:** To meet investors and analysts on Dec. 16.
- **Punjab National Bank:** To meet investors and analysts on Dec. 12.
- **Jaiprakash Associates and Jaypee Power Ventures board meeting** to consider on the various divestment initiatives

Market in Detailed (Updated at 8AM)

Indian Indices	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	62181.67	389.01	0.62	1.09	0.63	3.44	5.78
Nifty	18496.60	112.75	0.61	1.07	0.80	3.12	5.63
BSE M Cap	26095.56	116.80	0.45	0.86	2.48	0.27	1.51
BSE S Cap	29558.56	297.23	1.00	1.18	1.98	0.89	1.02
Nifty MC 100	32374.50	129.45	0.40	0.59	3.16	0.09	3.75
BSE Auto	29621.07	12.58	0.04	1.19	0.70	2.51	17.97
BSE Capgoods	34726.56	226.06	0.65	1.64	3.94	3.32	21.85
BSE FMCG	16748.57	118.63	0.71	1.97	3.33	4.47	19.60
BSE Metal	20569.30	238.46	1.15	0.73	2.11	6.82	3.85
BSE Oil&Gas	20343.90	183.04	0.89	0.77	1.90	0.91	10.89
BSE Healthcare	23379.31	35.63	0.15	2.29	1.16	0.59	6.94
BSE Power	4543.05	42.54	0.93	1.42	6.48	12.70	26.22
BSE Realty	3562.66	55.69	1.54	3.46	0.24	6.90	12.70
BSE ConsDur	40801.81	53.14	0.13	1.55	2.27	6.08	5.82
BSE Bank	49698.80	46.59	0.09	1.06	3.32	6.95	17.99
BSE IT	29349.86	901.26	2.98	5.33	1.24	1.07	16.93

LME	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1788.30	9.34	0.52	1.09	0.95	3.68	0.29
Silver(\$/Ounce)	23.26	0.21	0.91	4.52	7.16	17.48	4.79
Aluminium	2447.25	23.01	0.93	2.79	6.22	7.62	6.84
Copper	8507.00	17.75	0.21	0.88	4.84	7.36	10.84
Zinc	3286.00	17.00	0.52	6.51	14.61	3.24	1.53
Lead	2192.00	6.75	0.31	0.10	5.13	14.45	4.92

Currency	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	82.28	0.16	0.19	1.17	1.03	3.27	8.21
USD Index	105.18	0.36	0.35	0.11	1.05	2.91	9.45
YUAN	6.99	0.03	0.41	0.35	1.17	0.87	8.87
GBP	1.22	0.00	0.35	0.21	3.91	4.56	7.57
EUR	1.05	0.00	0.29	0.17	1.76	3.82	6.87
YEN	136.93	0.37	0.27	0.13	2.16	4.32	17.08

Agro Commodities	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	158.15	0.55	0.35	2.74	2.59	28.97	32.26
Cotton	81.19	0.24	0.30	3.18	5.95	20.69	6.25
Sugar	19.60	0.08	0.41	0.62	1.14	9.93	6.46
Wheat	740.75	6.50	0.89	0.24	11.31	15.17	6.29
Soybean	1471.50	12.25	0.83	2.35	1.48	1.39	17.84

Global Indices	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	33476.46	305.02	0.90	2.77	0.80	3.38	6.93
Nasdaq	11004.62	77.38	0.70	3.99	2.81	10.29	29.60
S&P 500	3934.38	29.13	0.73	3.37	1.47	4.28	16.50
FTSE100	7476.63	4.46	0.06	1.05	2.17	0.05	2.54
CAC40	6677.64	30.33	0.46	0.96	1.26	5.43	4.49
DAX	14370.72	106.16	0.74	1.09	1.03	7.23	8.02
Mexico IPC	50466.25	612.45	1.20	1.50	2.87	5.44	1.46
Brazil Bovespa	107519.6	270.52	0.25	3.94	4.22	5.19	0.22
Russian RTS	1099.12	2.49	0.23	0.76	5.10	14.18	31.83
Japan Nikkei	27824.10	78.13	0.28	0.01	1.56	2.52	2.16
Hang Seng	19660.04	243.92	1.23	0.71	13.46	1.52	18.08
Taiwan Index	14553.13	151.46	1.03	2.85	3.90	1.71	18.36
Shanghai Comp	3192.40	15.04	0.47	0.62	3.39	2.15	12.94
KOSPI	2371.10	18.30	0.77	2.01	4.53	0.57	21.24
Malaysia KLCI	1470.34	6.85	0.46	0.08	0.15	1.84	1.25
Jakarta Comp	6666.46	46.22	0.69	4.56	5.93	8.07	0.24
Philippine SE	6580.48	0.36	0.01	1.40	4.67	2.01	8.50
Thai Exch	1623.13	2.64	0.16	1.54	0.86	2.56	0.30

Freight	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1386.00	1.00	0.07	4.68	2.29	10.35	57.64
Baltic Dirty	2110.00	21.00	1.01	4.95	11.40	46.63	168.79
SG Dubai HY	25.48	2.40	10.40	18.79	23.39	24.23	638.55

Energy Markets	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	71.34	0.33	0.46	7.25	19.80	18.72	0.45
BRENT Crude	76.20	0.13	0.17	7.80	19.26	15.87	7.05
Natural Gas	6.88	0.62	9.98	23.15	9.66	19.36	62.06

Bond Markets	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	3.58	0.00	0.00	0.13	6.14	6.57	141.17
UK	3.18	0.09	2.98	0.86	7.98	2.78	321.33
Brazil	5.73	0.01	0.11	0.92	12.22	0.44	23.91
Japan	0.25	0.00	1.56	1.18	4.13	0.80	350.00
Australia	3.37	0.08	2.31	0.15	7.75	7.14	106.18
India	7.30	0.01	0.14	1.07	1.21	2.59	14.95
Switzerland	1.16	0.10	9.57	9.37	5.96	14.80	490.54
Germany	1.93	0.11	6.21	4.15	11.00	13.84	647.59

Taking global cues, the Nifty is expected to open flat around 18500 and likely to remain range-bound in the price band of 18400-18600.

The Nifty previous session ended 0.61% down at 18496.60. It opened on a flat note and remained range-bound towards ending in red. Bearish engulfing on daily after a decent rally might be a sign of trend reversal. Hence, staying cautious on rise around 18600 levels is advised. Chart pattern suggesting range bound oscillation with a negative bias in the price band of 18400-18600 is likely. Index majors seen making a double top pattern, which is a massive concern.

On the Nifty hourly chart, massive negative divergence in RSI suggesting the benchmark index may remain stuck in the price band of 18400-18600. Staying cautious on rise is advised.

Nifty patterns on multiple periods suggesting; it ended the week with a bearish candle. Being extremely overbought on daily, the Benchmark Index may see profit booking on rise. Massive resistance is placed around 18600 levels. Hence, staying cautious on rise is advised.

The Bank Nifty previous session ended 0.05% up at 43773.10. It might get into the trading range of 42500-43900.

The Financial Nifty Fut trading range likely to be 19300-19600.

Nifty Crucial Supports & Resistances-

Supports- 18400, 18200 Resistances- 18550, 18600

Open Positional Calls-

T+15 INST POSITIONAL SELL-

| Fut Segment | ITC @ 350-355, TGT- 325, Closing SL- above 370

T+15 INST POSITIONAL SELL-

| Fut Segment | HDFC @ 2640-2660, TGT- 2520, Closing SL- above 2730

T+15 INST POSITIONAL SELL-

| Fut Segment | HDFC BANK @ 1620-1640, TGT- 1530, Closing SL- above 1680

T+15 INST POSITIONAL BUY-

| Cash Segment | PAGE IND @ 46500-45500, TGT- 49500, Closing SL- below 44000

T+15 INST POSITIONAL SELL-

| Fut Segment | SBIN @ 610-615, TGT- 575, Closing SL- above 635

T+15 INST POSITIONAL SELL-

| Fut Segment | CAN BANK @ 330-335, TGT- 295, Closing SL- above 355

T+15 INST POSITIONAL SELL-

| Fut Segment | M&M @ 1320-1340, TGT- 1230, Closing SL- above 1380

- **Kalpataru Power Transmission:** The company raised Rs 99 crore via allotment of non-convertible debentures on a private placement basis.
- **PSP Projects:** The company received a letter of intent from Nila Spaces for a project worth Rs 121.51 crore to construct high-rise residential towers.
- **Emami:** The company increased its shareholding in subsidiary Brillare Science from 77.53% to 80.59%.
- **Bank of Baroda:** The bank hike MCLR rates in the range of 25-30 basis points across tenors, with effect from Dec. 12.
- **IDFC:** The scheme of amalgamation for the merger of wholly owned subsidiary companies IDFC Alternatives, IDFC Trustee Co., IDFC Projects with IDFC became operative from Dec. 9.
- **Bharti Airtel:** After receipt of notice for conversion of FCCBs of principle value of \$8.6 mn from certain holders of FCCBs, board members have approved allotment of 11.88 lakh shares at conversion price of Rs 521 per share to such FCCBs holders.
- **Himatsingka Seide:** Board will meet on December 15 to consider fund raising up to Rs 108 crore. They will also consider an issue of NCDs up to Rs 500 crore, to identified investors.
- **NTPC:** Commences commercial operations of first part capacity of 162.27 MW out of 230 MW Ettayapuram Solar PV Project.
- **Jaypee Power:** Meeting of board to apprise the board of the recommendations of the audit committee to consider the proposal of divestment of Jaypee Nigrie Cement Grinding Unit.
- **Zydus Lifesciences:** Receives two final approvals from the USFDA for Silodosin capsules and Pregabalin capsules. The drugs will be manufactured at the group's formulation manufacturing facility at Moraiya, Ahmedabad, India. Silodosin capsules had annual sales of \$14 million in the United States according to IQVIA data. Pregabalin capsules had annual sales of \$242 million in the United States according to IQVIA data.

Dollar Up, Stocks Down as Traders Eye Rate Paths

The dollar edged higher and stocks declined in Asia at the start of a pivotal week for markets, with interest rate decisions due from the Federal Reserve, the European Central Bank and a host of their peers. The greenback rose versus all of its Group-of-10 counterparts while an index of Asian equities fell, ending a two-day winning streak. A late-day slide in US stocks on Friday shattered the calm that prevailed throughout most of the trading session, with the S&P 500 closing near the day's lows. The Dow Jones Industrial Average notched its worst weekly drop since September. US stock futures fell in Asia on Monday. The Treasury 10-year yield was little changed after a jump on Friday that took it to just below 3.6%. Yields for government bonds in Australia and New Zealand rose. Recession fears have resurfaced ahead of the Fed decision Wednesday, when policymakers are expected to downshift to a 50 basis points hike. Yet officials including Chair Jerome Powell have also stressed that borrowing costs will need to remain restrictive for some time, putting them at odds with some investors looking for rate cuts later in 2023. The ECB follows on Thursday, with consensus estimates for it to also deliver a 50 basis points hike. Markets also have to contend with decisions this week from the Bank of England and monetary authorities in Mexico, Norway, the Philippines, Switzerland and Taiwan.

Oil Rebounds as Key Pipeline Remains Shut and China Eases Curbs

Oil rebounded as a key North American pipeline remained shut and on the potential boost to demand from the easing of virus curbs in China. West Texas Intermediate rose toward \$72 a barrel after collapsing 11% last week. TC Energy Corp. is continuing recovery efforts at its shuttered Keystone pipeline - which links fields in Canada to refiners on the US Gulf Coast — and a date for a restart hasn't yet been set, according to a statement on Sunday. China has been moving away from its Covid Zero policy following a wave of protests, even as the virus continues to spread, offering prospects for a revival in energy consumption in the world's largest crude importer. That's helping to offset concerns that the US may be headed for a recession after the Federal Reserve aggressively hiked interest rates to quell inflation.

Amgen Is Said in Talks to Buy Horizon After Sanofi Drops Out

Amgen Inc. is in talks to buy Horizon Therapeutics Plc in what would be its biggest-ever acquisition, according to people familiar with the matter, after Sanofi SA dropped out of the running. The US biotechnology giant is in advanced discussions with Horizon and a deal may be announced in the coming days, one of the people said, asking not to be identified discussing confidential information. The deal or announcement could be delayed and talks could still fall apart, the people said. Horizon shares have surged 24%, to \$97.29, since Nov. 29, when it disclosed Amgen, Sanofi, and a Johnson & Johnson unit were in preliminary talks toward a possible acquisition. That pushed its market value to \$22 billion, prompting Sanofi to back out Sunday, as J&J did earlier this month. Amgen has a market value of about \$149 billion after rising 24% this year. Sanofi said earlier on Sunday that it won't proceed with an offer for Horizon because the "transaction price expectations do not meet our value creation criteria." A takeover by the French drugmaker would have been one of its largest.

Auto / Auto Ancillaries

[CNG-powered vehicles increase share in car sales to 10%](#)

Banking & Finance

[RBI shortlists 7 global consultancy firms to use AI, ML to improve regulatory supervision](#)

[Private equity firms tap experts to give investee companies a boost](#)

[Borrowers don't have to be told individually about change in rates: Consumer court](#)

Metals/Mining/Power

[Govt will take all possible measures to meet 230 GW peak demand in April '23: Power Secretary](#)

[Power deficit in November falls to 0.2 per cent from 2 per cent in April](#)

[India's G20 presidency to play key role in clean energy push](#)

[All coal mines allocation are through open auction, says Kishan Reddy](#)

FMCG/Retail/Textiles/Agri

[Convenience food, premium packs countering FMCG slide](#)

[Tata Group plans to open 100 small exclusive Apple stores](#)

[Appliance makers expect robust growth from heating products this winter](#)

IT/Telecom/Media

[NDTV to give 2 board seats to Adani group firm](#)

[Fund infusion by January-February must for Vodafone Idea survival, say government officials](#)

[Trai releases consultation paper on data communication services between aircraft, ground stations](#)

Pharma/Fertilizers/Healthcare/Chemicals

[Glenmark gets warning letter from USFDA for lapses at Goa plant](#)

Hospitality/Aviation

[Indian hotels well positioned for a stronger show in H2 of this fiscal](#)

[PM Modi inaugurates Mopa International Airport in Goa](#)

[PM Modi inaugurates Goa's second airport; to start operations from January 5](#)

[Mopa International Airport in Goa named after former Defence Minister Manohar Parrikar](#)

[Air India nears historic order for up to 500 jets](#)

[Boeing says India is key nation for its sustainable aerospace programme](#)

Analyst Certification:

We /I, Jaydeb dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit's that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
